Nalmefene
Top View
- Opioid Receptor Research Using ALZET Osmotic Pumps
- TIP 40: Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction: Treatment Improvement Protocol (TIP) Series 40
- Distinct Effects of Nalmefene on Dopamine Uptake Rates and Kappa Opioid Receptor Activity in the Nucleus Accumbens Following Chronic Intermittent Ethanol Exposure
- House Bill No. 2038
- Guideline for CYP2D6, OPRM1, and COMT Genotype and Select Opioid
- Controlled Substances List (Adopted by Alabama State Board of Health on January 20, 2021, Effective January 20, 2021)
- The Effects of Herkinorin, the First Mu-Selective Ligand from a Salvinorin A-Derived Scaffold, in a Neuroendocrine Biomarker Assay in Nonhuman Primates
- Efficacy of Ketamine in the Treatment of Substance Use Disorders
- S21. Opioids.Pdf
- Expand Therapeutic Options for Opioid Addiction and Overdose 1
- Benefits and Risks of Pharmaceutical Opioids
- Ketamine for Depression: What Psychologists Need to Know
- WO 2016/086194 Al June 2016 (02.06.2016) W P O P C T
- United States Patent (19) 11 Patent Number: 4,692,451 Dodman Et Al
- Understanding and Addressing Substance Use Disorders As
- Drug Misuse in Adolescents Presenting to the Emergency Department
- Review Procedural Sedation and Analgesia in Children
- Free PDF Download